Pentoxifylline attenuated the renal disease progression in rats with remnant kidney

Journal of the American Society of Nephrology

Volumn 13, Issue 12, 2002, Pages 2916-2929

  Lin, Shuei Liong ^a,b,c   Chen, Yung Ming ^a,b   Chien, Chiang Ting ^a,c   Chiang, Wen Chih ^a,c   Tsai, Chien Chen ^a,b   Tsai, Tun Jun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN; CILAZAPRIL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 2; MONOCYTE CHEMOTACTIC PROTEIN 2; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; GENE EXPRESSION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; MESANGIUM CELL; MITOGENESIS; MYOFIBROBLAST; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; ANIMAL; CELL CULTURE; CELL DIVISION; DISEASE COURSE; DOWN REGULATION; FIBROSIS; GENETICS; KIDNEY; MESANGIUM; METHODOLOGY; MITOSIS; NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; SMOOTH MUSCLE; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CELL DIVISION; CELLS, CULTURED; CHEMOKINE CCL2; CILAZAPRIL; DISEASE PROGRESSION; DOWN-REGULATION; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GLOMERULAR MESANGIUM; KIDNEY; KIDNEY DISEASES; MALE; MITOSIS; MUSCLE, SMOOTH; NEPHRECTOMY; NEPHRITIS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR;

EID: 0036892615     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000034909.10994.8A     Document Type: Article

References (44)

1. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318: 1657-1666, 1988
2. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307: 652-659, 1982
3. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309, 1992
4. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 7: 653-660, 1996
5. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW, Ziai F, Jiang T, Brenner BM, Mackenzie HS: Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 58: 1664-1676, 2000
6. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
7. Gruppo Italiano Studi Epidermiologici in Nefrologia (The GISEN Group): Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathies. Lancet 349: 1857-1863, 1997
8. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549, 1999
9. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58: 2084-2092, 2000
10. Fuhihara CK, Avancini DA, Zatz R, Noronha IL: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519, 1998
11. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58: 51-61, 2000
12. Ward A, Clissold SI: Pentoxifylline. A review of its pharmaco-dynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 34: 50-97, 1987
13. Jaimes EA, del Castillo D, Rutherford MS, Raij L: Countervailing influence of tumor necrosis factor-alpha and nitric oxide in endotoxemia. J Am Soc Nephrol 12: 1204-1210, 2001
14. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, Mendez ML, Garcia J: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999
15. Duclous D, Bresson-Vautrin C, Chalopin JM: Use of pentoxifylline in membranous nephropathy. Lancet 357: 1672-1673, 2001
16. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, Kitze B, Weber T, Borner T, Poser S: Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64: 193-200, 1996
17. Fujimoto T, Nakamura T, Furuya T, Nakane S, Shirabe S, Kambara C, Hamasaki S, Yoshimura T, Eguchi K: Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type I-associated myelopathy. Intern Med 38: 717-721, 1999
18. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 70: 91-100, 1995
19. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Muller GA: Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 15: 1535-1546, 2000
20. Hewitson TD, Martic M, Kelynack KJ, Pedagogos E, Becker GJ: Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 20: 82-88, 2000
21. Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC: Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties. Transplant 64: 1404-1407, 1997
22. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ: Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56: 932-943, 1999
23. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43: 97-102, 1995
24. Chien CT, Lee PH, Chen CF, Ma MC, Lai MK, Hsu SM: De Novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J Am Soc Nephrol 12: 973-982, 2001
25. Herren B, Weyer KA, Rouge M, Lotscher P, Pech M: Conservation in sequence and affinity of human and rodent PDGF ligands and receptors. Biochim Biophys Acta 1173: 294-302, 1993
26. Shimasaki S, Emoto N, Koba A, Mercado M, Shibata F, Cooksey K, Baird A, Ling N: Complementary DNA cloning and sequencing of rat ovarian basic fibroblast growth factor and tissue distribution study of its mRNA. Biochem Bioph Res Co 157: 256-263, 1988
27. Xu J, Smock SL, Safadi FF, Rosenzweig AB, Odgren PR, Marks SC Jr, Owen TA, Popoff SN: Cloning the full-length cDNA for rat connective tissue growth factor: Implications for skeletal development. J Cell Biochem 77: 103-115, 2000
28. Schiller B, Moran J: Focal glomerulosclerosis in the remnant kidney model: An inflammatory disease mediated by cytokines. Nephrol Dial Transplant 12: 430-437, 1997
29. Tang WW, Qi M, Warren JS, Van GY: Chemokine expression in experimental tubulointerstitial nephritis. J Immunol 159: 870-876, 1997
30. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DCH: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor κB in proximal tubule cells. J Am Soc Nephrol 10: 1204-1213, 1999
31. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994
32. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11: 25-38, 2000
33. Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M: Expression of connective tissue growth factor in human renal fibroblasts: Regulatory roles of RhoA and cAMP. J Am Soc Nephrol 12: 1853-1861, 2001
34. Wu LL, Yang N, Goe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and Myofibroblast Proliferation in Remnant Kidney: Role of Angiotensin II. 52[Suppl 63]: 221-225, 1997
35. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gibert RE, Cooper M, Atkins RC, Lan HY: Local macrophages and myofibroblast proliferation in progressive injury in the rat remnant kidney. Nephrol Dial Transplant 13: 1967-1974, 1998
36. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9: 1213-1224, 1998
37. Strutz F, Ziesberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, Muller GA: Basic fibroblast growth factor (FGF-2) expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 57: 1521-1538, 2000
38. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161: 430-439, 1998
39. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsuhima K, Takeshita A: Important role of local angiotensin II activity mediated via type I receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101: 305-310, 2001
40. Krakauer T: Induction of CC cheekiness in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J Leukoc Biol 66: 158-164, 1999
41. Wang W, Tam WF, Hughes CC, Rath S, Sen R: c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6: 165-174, 1997
42. Hecht M, Muller M, Lohmann-Matthes ML, Emmendorffer A: In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 57: 242-249, 1995
43. Balazs C, Kiss H, Farid NR: Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblast. Horm Metab Res 30: 496-499, 1998
44. Sathe SS, Tsigler D, Sarai A, Kumar P: Pentoxifylline impairs macrophage defense against Mycobacterium avium complex. J Infect Dis 172: 863-866, 1995